Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

The summary for the Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional): Reissue PAR-21-233 - The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. BPN-Biologics awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN-Biologics contractors (and thereby control the patent prosecution and licensing negotiations) for biotherapeutic candidates developed in this program.
Federal Grant Title: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
Federal Agency Name: National Institutes of Health (HHS-NIH11)
Grant Categories: Education, Environment, Health
Type of Opportunity: Discretionary
Funding Opportunity Number: PAR-24-294
Type of Funding: Cooperative Agreement
CFDA Numbers: 93.113, 93.121, 93.213, 93.242, 93.273, 93.279, 93.853, 93.866, 93.867
CFDA Descriptions: Information not provided
Current Application Deadline: August 18th, 2027
Original Application Deadline: August 18th, 2027
Posted Date: October 1st, 2024
Creation Date: October 1st, 2024
Archive Date: September 23rd, 2027
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Last Updated: October 1st, 2024
Applicants Eligible for this Grant
Small businesses
Additional Information on Eligibility
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement
https://grants.nih.gov/grants/guide/pa-files/PAR-24-294.html
Grant Announcement Contact
NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)
Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational E...
Environmental Health Disparities Centers (P50) Clinical Trial Optional
Outstanding New Environmental Scientist Award (ONES)
Environmental Health Sciences Core Center Grants
Leiomyomata Uteri: Basic Science and Translational Research
More Grants from the National Institutes of Health
CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research ...
NINDS Sustainable Transformation of Institutional Research Rigor (STIRR) Program (RC2 - Cl...
Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Cl...
Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-te...
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com